IMNM
Income statement / Annual
Last year (2025), Immunome Inc's total revenue was $6.94 M,
a decrease of 23.23% from the previous year.
In 2025, Immunome Inc's net income was -$212.39 M.
See Immunome Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$6.94 M |
$9.04 M |
$14.02 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.96 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$755.00 K
|
$615.00 K
|
$521.00 K
|
| Gross Profit |
$3.99 M
|
$9.04 M
|
$14.02 M
|
$0.00
|
$0.00
|
-$755.00 K
|
-$615.00 K
|
-$521.00 K
|
| Gross Profit Ratio |
0.57
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$174.33 M
|
$129.54 M
|
$23.09 M
|
$23.27 M
|
$14.11 M
|
$6.73 M
|
$8.82 M
|
$6.88 M
|
| General & Administrative Expenses |
$43.77 M
|
$32.96 M
|
$19.66 M
|
$13.63 M
|
$11.09 M
|
$0.00
|
$1.53 M
|
$866.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$43.77 M
|
$32.96 M
|
$19.66 M
|
$13.63 M
|
$11.09 M
|
$4.78 M
|
$1.53 M
|
$866.00 K
|
| Other Expenses |
$0.00
|
$152.34 M
|
$80.80 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$218.10 M
|
$314.84 M
|
$123.55 M
|
$36.90 M
|
$25.20 M
|
$11.51 M
|
$10.35 M
|
$7.74 M
|
| Cost And Expenses |
$221.05 M
|
$314.84 M
|
$123.55 M
|
$36.90 M
|
$25.20 M
|
$12.26 M
|
$10.35 M
|
$7.74 M
|
| Interest Income |
$11.72 M
|
$12.84 M
|
$2.72 M
|
$5.00 K
|
$10.00 K
|
$1.00 K
|
$10.00 K
|
$39.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$5.00 K
|
$10.00 K
|
$38.00 K
|
$106.00 K
|
$141.00 K
|
| Depreciation & Amortization |
$2.96 M
|
$2.10 M
|
$728.00 K
|
$631.00 K
|
$755.00 K
|
$755.00 K
|
$615.00 K
|
$521.00 K
|
| EBITDA |
-$211.16 M |
-$151.35 M |
-$28.00 M |
-$36.27 M |
-$24.45 M |
-$17.04 M |
-$9.72 M |
-$7.18 M |
| EBITDA Ratio |
-30.42
|
-16.74
|
-2
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-30.85
|
-33.82
|
-7.81
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.72 M
|
$12.84 M
|
$2.72 M
|
$5.00 K
|
$493.00 K
|
-$5.58 M
|
-$96.00 K
|
-$102.00 K
|
| Income Before Tax |
-$212.39 M
|
-$292.96 M
|
-$106.81 M
|
-$36.90 M
|
-$24.71 M
|
-$17.84 M
|
-$10.44 M
|
-$7.85 M
|
| Income Before Tax Ratio |
-30.6
|
-32.4
|
-7.62
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$39.00 K
|
| Net Income |
-$212.39 M
|
-$292.96 M
|
-$106.81 M
|
-$36.90 M
|
-$24.71 M
|
-$17.84 M
|
-$10.55 M
|
-$7.85 M
|
| Net Income Ratio |
-30.6
|
-32.4
|
-7.62
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.43 |
-5 |
-5.38 |
-3.09 |
-2.14 |
-1.69 |
-1.84 |
-7.18 |
| EPS Diluted |
-2.43 |
-5 |
-5.38 |
-3.09 |
-2.14 |
-1.69 |
-1.84 |
-7.18 |
| Weighted Average Shares Out |
$87.35 M
|
$58.64 M
|
$19.84 M
|
$12.13 M
|
$11.54 M
|
$10.11 M
|
$5.74 M
|
$1.09 M
|
| Weighted Average Shares Out Diluted |
$87.35 M
|
$58.64 M
|
$19.84 M
|
$12.13 M
|
$11.54 M
|
$10.11 M
|
$5.74 M
|
$1.09 M
|
| Link |
|
|
|
|
|
|
|
|
